Turning Point Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Turning Point Therapeutics Inc (TPTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Turning Point Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 34M combined for tracked competitors (2.9% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-52.8% annualized vs trailing 12 months), vs decelerating (-75.3%) for its tracked peer group.
- Growth: Turning Point Therapeutics Inc generated -97.7% revenue growth year over year in Q2 2022, vs -7.0% for its tracked competitors combined.
- Profitability: Its -103,435.3% net margin compares with -3,172.5% for the peer group.
- Peer revenue share: Turning Point Therapeutics Inc accounted for 5.4% of combined revenue among its tracked peer group, down from 69.6% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.15M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TPTX Sales vs. its Competitors, Q2 2022
Turning Point Therapeutics Inc reported revenue contraction of 97.70 % year on year in Q2 2022, below its competitors' combined revenue change of -7.04 %.
With a net margin of -103,435.29 %, Turning Point Therapeutics Inc reported lower profitability than its competitors (-3,172.51 %).
Turning Point Therapeutics Inc generated 5.36 % of the combined sales of its peer group, down from 69.57 % a year earlier.
Turning Point Therapeutics Inc vs. its Competitors, Q2 2022
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Turning Point Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Turning Point Therapeutics Inc. | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Turning Point Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -97.7% for Turning Point Therapeutics Inc. Turning Point Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Turning Point Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Turning Point Therapeutics Inc. | No | - | - | Yes |
| Competitors combined (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TPTX Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 2 | Adial Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Vistagen Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Turning Point Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Turning Point Therapeutics Inc.
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Turning Point Therapeutics Inc. | 3,777.91 | 1.01 |
| Nuvectis Pharma inc | 479.38 | - |
| Marinus Pharmaceuticals Inc | 31.48 | 31.47 |
| Adial Pharmaceuticals Inc | 18.67 | - |
| Vistagen Therapeutics Inc | 12.63 | 2.50 |
| SUBTOTAL | 4,320.07 | 34.98 |
Sources: Turning Point Therapeutics Inc.'s official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Turning Point Therapeutics Inc. versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Turning Point Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Turning Point Therapeutics Inc. | 3,778 | 9,081 | -3,083,847 |
| Nuvectis Pharma inc | 479 | - | -2,328,846 |
| Marinus Pharmaceuticals Inc | 31 | 190,703 | -851,461 |
| Adial Pharmaceuticals Inc | 19 | - | -9,633,534 |
| Vistagen Therapeutics Inc | 13 | 61,000 | -1,649,268 |
| PEERS TOTAL | 542 | 150,964 | -1,316,388 |
Turning Point Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 64.89 % (avg) | +35.1 pp |
| Operating Margin | -34,185.81 % | industry median | -33,951.9 pp |
| EBITDA Margin | -33,540.08 % | -7.21 % (avg) | -33,532.9 pp |
| Capital Intensity (Capex / Revenue) | 349.90 % | 4.92 % (avg) | +345.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Turning Point Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 3.2x | 4.5x | -1.3x |
| Return on Equity | -37.45 % | industry aggregate | -56.09 % |
| Return on Invested Capital | -18.83 % | -2.95 % (avg) | -15.88 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Turning Point Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | -772.00 % |
| Return on Invested Capital | -13.35 % | -11.12 % | -11.48 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Turning Point Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 349.90 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Turning Point Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Turning Point Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Turning Point Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Turning Point Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Turning Point Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 33,951.9 points below the industry median.
- Return on equity 56.1 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-52.8% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (75.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-75.3% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Turning Point Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Turning Point Therapeutics Inc. | 7.92 | 21.01 | - |
| Nuvectis Pharma inc | 2.32 | 2.33 | - |
| Marinus Pharmaceuticals Inc | 2.93 | 2.83 | - |
| Adial Pharmaceuticals Inc | 4.21 | 4.88 | - |
| Vistagen Therapeutics Inc | 3.83 | 4.82 | 0.00 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Turning Point Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Turning Point Therapeutics Inc. | Q2 2022 | -97.7 % | - |
| Nuvectis Pharma inc | Q2 2026 | - | - |
| Marinus Pharmaceuticals Inc | Q3 2024 | +16.4 % | - |
| Adial Pharmaceuticals Inc | Q2 2026 | - | - |
| Vistagen Therapeutics Inc | Q2 2026 | +504.9 % | - |
| PEERS TOTAL | -20.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Turning Point Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Turning Point Therapeutics Inc. | Q2 2022 | - | +108.9 % |
| Nuvectis Pharma inc | Q2 2026 | - | - |
| Marinus Pharmaceuticals Inc | Q3 2024 | +56.9 % | +1,210.6 % |
| Adial Pharmaceuticals Inc | Q2 2026 | - | - |
| Vistagen Therapeutics Inc | Q2 2026 | - | - |
Turning Point Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Turning Point Therapeutics Inc. | - | - | - |
| Nuvectis Pharma inc | - | - | - |
| Marinus Pharmaceuticals Inc | - | - | - |
| Adial Pharmaceuticals Inc | - | - | - |
| Vistagen Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Turning Point Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Turning Point Therapeutics Inc. | - | 3,747.93 |
| Nuvectis Pharma inc | - | - |
| Marinus Pharmaceuticals Inc | - | 1.00 |
| Adial Pharmaceuticals Inc | - | - |
| Vistagen Therapeutics Inc | - | 5.05 |
| PEERS AVERAGE | - | 123.52 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.